IASO Biotherapeutics
Business Services · China · 201-500 Employees
View Company Info for Free
Overview
Headquarters
Building D Zhongdan Park 8-10 Xinjinhu R...Phone Number
+86 2558287610Website
www.iasobio.comRevenue
$76.1 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About IASO Biotherapeutics
Founded in 2017, IASO BIO is a clinical-stage biotechnology company dedicated to the development of innovative cell therapies for cancer. IASO BIO is located in ChinaExplore more
IASO Biotherapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is IASO Biotherapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
IASO Biotherapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Click to see if IASO Biotherapeutics had a recent Job posting/layoffs
Product Launch: Get notified when IASO Biotherapeutics launches new products
Check if IASO Biotherapeutics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at IASO Biotherapeutics
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on IASO Biotherapeutics recently announced quarterly report
Funding: Get notified immidiatlly once IASO Biotherapeutics has new funding data
Check out if IASO Biotherapeutics is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined IASO Biotherapeutics as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
IASO Biotherapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
IASO Biotherapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about IASO Biotherapeutics.
IASO Biotherapeutics financials insights
Gather financial insights about IASO Biotherapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series B
$60M
2021
Series C
$175M
IASO Biotherapeutics Tech Stack
A closer look at the technologies used by IASO Biotherapeutics
See more technologies
Most Recent Scoops
Project
Product Development, Product Management, Governmental Affairs & Regulation, Medical Research, Pharmaceuticals, Clinical Operations, Regulations
Project
Product Development, Product Management, Governmental Affairs & Regulation, Medical Research, Pharmaceuticals, Clinical Operations, Regulations
Project
Product Development, Research & Development, Product Management, Intellectual Property, Legal Affairs
Funding
New Hire
Executive Move
IASO Biotherapeutics News & Media
IASO Bio Establishes International Partnership with Instituto Butantan to Develop Innovative Therapy for Hematological Cancer
The agreement aims to expand access to the therapy in Brazil; The Technology is for patients who did not respond to conventional treatments. SHANGHAI and NANJING, China and PLEASANTON, Calif., April 10, 2026 /PRNewswire/ -- IASO Biotechnology ("IASO Bio"), today announced that it has...IASO Bio Has Received Clearance from Japan's PMDA to Initiate Clinical Trial for CAR-T Therapy Equecabtagene Autoleucel in Second- or Third-Line Multiple Myeloma
SHANGHAI and NANJING, China and PLEASANTON, Calif., March 24, 2026 /PRNewswire/ -- IASO Biotechnology ("IASO Bio"), a commercial-stage biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of novel cell therapies and biologics for...IASO Bio Presents Updated Results for Equecabtagene Autoleucel in High-Risk Newly Diagnosed Multiple Myeloma Patients at 2025 ASH
SHANGHAI and NANJING, China and PLEASANTON, Calif., Dec. 7, 2025 /PRNewswire/ -- IASO Biotechnology ("IASO Bio"), a commercial-stage biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of novel cell therapies and biologics for hematologic...IASO Bio Presents Updated Results for Equecabtagene Autoleucel in High-Risk Newly Diagnosed Multiple Myeloma Patients at 2025 ASH
SHANGHAI and NANJING, China and PLEASANTON, Calif., Dec. 8, 2025 /PRNewswire/ -- IASO Biotechnology ("IASO Bio"), a commercial-stage biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of novel cell therapies and biologics for hematologic malignancies and autoimmune diseases, announced the oral presentation of updated clinical data for its independently developed, fully human BCMA-targeted CAR-T cell therapy product, Equecabtagene Autoleucel (Equ
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding IASO Biotherapeutics
Sign Up For FreeTo access detailed company insights
Founded in 2017, IASO BIO is a clinical-stage biotechnology company dedicated to the development of innovative cell therapies for cancer. IASO BIO is located in China... Read More
